Engaged in advancing innovative solutions for large-scale market applications
Tel Aviv, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies and electric vehicle (“EV”) and charging solutions, announced today that Polyrizon Ltd. (“Polyrizon”), a privately held company in which Medigus owns 37.03%, has submitted a PCT (Patent Cooperation Treaty) application, following a submission to the United States Patent and Trademark Office for its innovative technology.
The patent refers to Polyrizon’s Capture and Contain (C&C™) platform. C&C™ platform is based on natural 3-D polymeric network tailored to optimally adhere to the nasal mucosal surface. The polymeric network creates a physical barrier that captures and contains biological threats in order to block their penetration. The C&C™ platform can be readily adapted for a wide range of applications to protect the human body from airborne threats such as allergens, viruses and mold.
Polyrizon is a biotech company, focused on the development and commercialization of innovative intranasal products.